Trevena Reports Third Quarter 2021 Results
15. November 2021 07:00 ET
|
Trevena Inc.
-- Advanced OLINVYK commercial launch with expanded field medical team and additional target markets Announced new OLINVYK cognitive function study vs. IV morphine, enrollment expected...
Trevena Adds Seasoned Biopharma Commercial Executive to Senior Leadership Team
11. November 2021 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena to Release Third Quarter 2021 Financial Results on November 15th, 2021
08. November 2021 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces Two OLINVYK® Presentations at ANESTHESIOLOGY® 2021
13. Oktober 2021 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces Results of TRV027 Proof-of-Concept Study in COVID-19 Patients
30. September 2021 07:00 ET
|
Trevena Inc.
-- 92% probability that TRV027 has a potential beneficial impact on primary endpoint of D-dimer levels, a biomarker associated with critical illness and mortality ~12 days lower average...
Trevena to Present at the Oppenheimer 2021 Fall Healthcare Life Sciences & MedTech Summit
17. September 2021 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
09. September 2021 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces Two OLINVYK® Abstracts Highlighting Safety Data Accepted at ANESTHESIOLOGY® 2021
30. August 2021 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Penn., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces Wake Forest Baptist Health Joining OLINVYK® Clinical Outcomes Study
25. August 2021 07:00 ET
|
Trevena Inc.
-- Study is being led by Cleveland Clinic; designed to evaluate potential benefit of OLINVYK on respiratory, GI, and cognitive function outcomes in postoperative patients Patient enrollment...
Trevena Reports Second Quarter 2021 Results
12. August 2021 07:00 ET
|
Trevena Inc.
Company reaffirms YE goal of 100 formulary wins OLINVYK respiratory physiology study currently enrolling, topline data expected by YE 2021 NIH / Vanderbilt University Medical Center-led...